ClinicalTrials.gg
CompletedNCT01964716Updated Mar 13, 2015Results posted

13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.

A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine and 13-valent pneumococcal conjugate vaccine in Pneumococcal Vaccines, sponsored by Pfizer. Completed at 2 sites in Gambia. Open to participants aged 42 Days to 70 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-13.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
42 Days to 70 Days
Sex
All
01

Study summary

This study will compare the immune responses of the infants who have been given 13vPnC in the mutidose vial formulation to the immune reponses of the infants who have been given 13vPnC in the single-dose syringe formulation.

It will also evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in all infants who are vaccinated.

02

Conditions studied

  • Pneumococcal Vaccines

Keywords

  • Prevenar 13
  • 13vPnC
  • Healthy Subjects
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
42 Days to 70 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 42 to 70 days at enrollment.
  • Determined by medical history, physical examination, and clinical judgment to be eligible for the study
  • Weight of 3.5 kg or greater at the time of enrollment

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination with licensed or pneumococcal vaccine.
  • A previous anaphylactic reaction to any vaccine or vaccine-related component.
  • to vaccination with pneumococcal conjugate vaccine.
  • Receipt of blood products or gamma-globulin since birth
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (actual)

Study arms

  • Experimental
    Multidose Vial Group

    Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the multidose vial formulation. Each dose is 0.5 mL

    Biological: 13-valent pneumococcal conjugate vaccine

  • Active comparator
    Single-Dose Syringe Group

    Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the single-dose syringe formulation. Each dose is 0.5 mL

    Biological: 13-valent pneumococcal conjugate vaccine

Interventions

  • Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (multidose vial formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.

  • Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (single-dose syringe formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal To (>=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After the Infant Series for Each Vaccine Group

    Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. Exact 2-sided confidence interval (Clopper and Pearson) based on the observed proportion of participants. Here "n"= participants with valid and determinate IgG concentration to the given serotype.

    Time frame: 1 month after the infant series

  2. Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series for Each Vaccine Group

    Antibody GMC for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. CIs were back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations. Here "n"= participants with valid and determinate IgG concentration to the given serotype.

    Time frame: 1 month after the infant series

  3. Number of Participants Reporting Local Reaction Within 5 Days After Dose 1 in MDV and SDS Group

    Local reactions were reported within 5 days (day 2 to day 6) using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurt if gently touched; Moderate (hurt if gently touched with crying); Severe (caused limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.1 to 7.0 cm); Severe (greater than \[\>\] 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 5 days after Dose 1(Day 2 to Day 6) of the infant series

  4. Number of Participants Reporting Local Reaction Within 5 Days After Dose 2 in MDV and SDS Group

    Local reactions were reported within 5 days (day 2 to day 6) using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurt if gently touched; Moderate (hurt if gently touched with crying); Severe (caused limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.1 to 7.0 cm); Severe (greater than \[\>\] 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 5 days after Dose 2 (Day 2 to Day 6) of the infant series

  5. Number of Participants Reporting Local Reaction Within 5 Days After Dose 3 in MDV and SDS Group

    Local reactions were reported within 5 days (day 2 to day 6) using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurt if gently touched; Moderate (hurt if gently touched with crying); Severe (caused limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.1 to 7.0 cm); Severe (greater than \[\>\] 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 5 days after Dose 3 (Day 2 to Day 6) of the infant series

  6. Number of Participants Reporting Systemic Events Within 5 Days After Dose 1 in MDV and SDS Group

    Systemic events (any fever greater than or equal to \[\>=\] 38.0 degrees Celsius \[C\], decreased appetite was scaled as; Moderate (decreased oral intake); Severe (refusal to feed). Irritability scaled as; Mild (easily consolable); Moderate (requiring increased attention); Severe (Inconsolable, crying that cannot be comforted). Increased sleep was scale as; mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (Disabling not interested in usual daily activity) and use of antipyretic medication were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 5 days after Dose 1 (Day 2 to Day 6) of infant series

  7. Number of Participants Reporting Systemic Events Within 5 Days After Dose 2 in MDV and SDS Group

    Systemic events (any fever greater than or equal to \[\>=\] 38.0 degrees Celsius \[C\], decreased appetite was scaled as; Moderate (decreased oral intake); Severe (refusal to feed). Irritability scaled as; Mild (easily consolable); Moderate (requiring increased attention); Severe (Inconsolable, crying that cannot be comforted). Increased sleep was scale as; mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (Disabling not interested in usual daily activity) and use of antipyretic medication were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 5 days after Dose 2 (Day 2 to Day 6) of infant series

  8. Number of Participants Reporting Systemic Events Within 5 Days After Dose 3 in MDV and SDS Group

    Systemic events (any fever greater than or equal to \[\>=\] 38.0 degrees Celsius \[C\], decreased appetite was scaled as; Moderate (decreased oral intake); Severe (refusal to feed). Irritability scaled as; Mild (easily consolable); Moderate (requiring increased attention); Severe (Inconsolable, crying that cannot be comforted). Increased sleep was scale as; mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (Disabling not interested in usual daily activity) and use of antipyretic medication were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 5 days after Dose 3 (Day 2 to Day 6) of infant series

  9. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Infant Series

    An AE was any untoward medical occurrence in a participants who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 to 42 days after last dose that were absent before treatment or that worsened relative to pretreatment state

    Time frame: Dose 1 up to 28 to 42 days after dose 3

  10. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Prior to Dose 1

    An AE was any untoward medical occurrence in a participants who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Adverse events were also reported in participants who provided consent but were not randomized in this study. The data of these participants has been reported under 'Screened Only' arm.

    Time frame: Informed consent up to Dose 1

Secondary outcomes

  1. Percentage of Participants Achieving a Serotype-Specific Opsonophagocytic Activity (OPA) Titer >= Lower Limit of Quantitation (LLOQ) 1 Month After Infant Series

    Percentage of participants achieving OPA Titer \>= lower limit of quantitation (LLOQ) along with 95% CI for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Exact 2-sided confidence interval (Clopper and Pearson) based on the observed proportion of participants. Here "n"= Number of participants with an antibody titer ≥ LLOQ for the given serotype.

    Time frame: 1 month after the infant series

  2. Serotype-Specific Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After the Infant Series

    Antibody geometric mean titers as measured by OPA assay for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. GMTs were calculated using all participants with available data for the specified blood draw. CIs were back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers. Here "n"= participants evaluable =specified category.

    Time frame: 1 month after the infant series

07

Results

Posted Mar 13, 2015

Participant flow

Participant flow — Overall Study
Milestone13vPnC Multi-dose Vial (MDV)13vPnC Single-Dose Syringe (SDS)
Started250250
Vaccinated dose 1250250
Vaccinated dose 2249248
Vaccinated dose 3247244
Completed245244
Not completed56
Withdrew: Withdrawal by subject23
Withdrew: Lost to follow-up12
Withdrew: No longer met eligibility criteria11
Withdrew: Death10

Outcome measures

PrimaryPercentage of Participants Achieving a Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal To (>=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After the Infant Series for Each Vaccine Group

Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. Exact 2-sided confidence interval (Clopper and Pearson) based on the observed proportion of participants. Here "n"= participants with valid and determinate IgG concentration to the given serotype.

Time frame:
1 month after the infant series
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal To (>=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After the Infant Series for Each Vaccine Group
percentage of participants13vPnC Multi-dose Vial (MDV)13vPnC Single-Dose Syringe (SDS)
Serotype 1 (n=245,244)99.2 (97.1 to 99.9)100.0 (98.5 to 100.0)
Serotype 3 (n=245,243)98.8 (96.5 to 99.7)99.6 (97.7 to 100.0)
Serotype 4 (n=245,244)99.6 (97.7 to 100.0)99.6 (97.7 to 100.0)
Serotype 5 (n=245,244)95.9 (92.6 to 98.0)97.1 (94.2 to 98.8)
Serotype 6A (n=243,244)96.3 (93.1 to 98.3)97.5 (94.7 to 99.1)
Serotype 6B (n=245,244)95.1 (91.6 to 97.4)95.1 (91.6 to 97.4)
Serotype 7F (n=245,244)99.6 (97.7 to 100.0)100.0 (98.5 to 100.0)
Serotype 9V (n=245,244)98.0 (95.3 to 99.3)98.4 (95.9 to 99.6)
Serotype 14 (n=245,244)97.6 (94.7 to 99.1)98.4 (95.9 to 99.6)
Serotype 18C (n=245,244)99.2 (97.1 to 99.9)98.0 (95.3 to 99.3)
Serotype 19A (n=245,244)99.6 (97.7 to 100.0)98.8 (96.4 to 99.7)
Serotype 19F (n=245,244)96.7 (93.7 to 98.6)97.1 (94.2 to 98.8)
Serotype 23F (n=245,244)95.9 (92.6 to 98.0)95.9 (92.6 to 98.0)
Statistical analysis
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: -0.8 · 97.5% CI -3.4 to 1.2
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: -0.8 · 97.5% CI -3.7 to 1.6
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: 0.0 · 97.5% CI -2.3 to 2.4
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: -1.2 · 97.5% CI -5.4 to 2.8
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: -1.2 · 97.5% CI -5.3 to 2.6
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: 0.0 · 97.5% CI -4.7 to 4.7
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: -0.4 · 97.5% CI -2.7 to 1.6
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: -0.4 · 97.5% CI -3.8 to 2.8
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: -0.8 · 97.5% CI -4.3 to 2.5
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: 1.2 · 97.5% CI -1.6 to 4.5
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: 0.8 · 97.5% CI -1.6 to 3.6
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percentage difference: -0.4 · 97.5% CI -4.4 to 3.5
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: 0.0 · 97.5% CI -4.3 to 4.4
PrimaryGeometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series for Each Vaccine Group

Antibody GMC for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. CIs were back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations. Here "n"= participants with valid and determinate IgG concentration to the given serotype.

Time frame:
1 month after the infant series
Reported as:
Geometric mean · microgram per milliliter (mcg/mL)
Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series for Each Vaccine Group
microgram per milliliter (mcg/mL)13vPnC Multi-dose Vial (MDV)13vPnC Single-Dose Syringe (SDS)
Serotype 1 (n=245,244)4.59 (4.11 to 5.12)4.45 (4.01 to 4.93)
Serotype 3 (n=245,243)1.38 (1.29 to 1.49)1.74 (1.62 to 1.87)
Serotype 4 (n=245,244)5.30 (4.84 to 5.81)5.28 (4.76 to 5.85)
Serotype 5 (n=245,244)2.00 (1.79 to 2.22)1.98 (1.79 to 2.20)
Serotype 6A (n=243,244)2.25 (2.02 to 2.50)2.19 (1.96 to 2.44)
Serotype 6B (n=245,244)3.42 (2.91 to 4.02)3.24 (2.77 to 3.78)
Serotype 7F (n=245,244)3.92 (3.59 to 4.27)4.18 (3.83 to 4.55)
Serotype 9V (n=245,244)2.83 (2.56 to 3.13)2.75 (2.49 to 3.04)
Serotype 14 (n=245,244)4.78 (4.06 to 5.63)4.96 (4.27 to 5.77)
Serotype 18C (n=245,244)3.47 (3.17 to 3.79)2.72 (2.46 to 3.00)
Serotype 19A (n=245,244)6.49 (5.70 to 7.38)6.44 (5.66 to 7.32)
Serotype 19F (n=245,244)5.19 (4.59 to 5.86)5.00 (4.43 to 5.63)
Serotype 23F (n=245,244)2.61 (2.30 to 2.97)2.17 (1.92 to 2.46)
Statistical analysis
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmc ratio: 1.03 · 97.5% CI 0.87 to 1.22
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmc ratio: 0.79 · 97.5% CI 0.71 to 0.90
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmc ratio: 1.00 · 97.5% CI 0.86 to 1.18
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmc ratio: 1.01 · 97.5% CI 0.85 to 1.19
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmc ratio: 1.03 · 97.5% CI 0.86 to 1.22
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmc ratio: 1.06 · 97.5% CI 0.82 to 1.36
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmc ratio: 0.94 · 97.5% CI 0.82 to 1.08
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmc ratio: 1.03 · 97.5% CI 0.87 to 1.21
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmc ratio: 0.96 · 97.5% CI 0.75 to 1.24
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmc ratio: 1.28 · 97.5% CI 1.09 to 1.49
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmc ratio: 1.01 · 97.5% CI 0.82 to 1.24
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmc ratio: 1.04 · 97.5% CI 0.85 to 1.26
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmc ratio: 1.20 · 97.5% CI 0.98 to 1.48
PrimaryNumber of Participants Reporting Local Reaction Within 5 Days After Dose 1 in MDV and SDS Group

Local reactions were reported within 5 days (day 2 to day 6) using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurt if gently touched; Moderate (hurt if gently touched with crying); Severe (caused limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.1 to 7.0 cm); Severe (greater than \[\>\] 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 5 days after Dose 1(Day 2 to Day 6) of the infant series
Reported as:
Number · participants
Number of Participants Reporting Local Reaction Within 5 Days After Dose 1 in MDV and SDS Group
participants13vPnC Multi-dose Vial (MDV)13vPnC Single-Dose Syringe (SDS)
Redness: Any10
Redness: Mild10
Redness: Moderate00
Redness: Severe00
Swelling: Any10
Swelling: Mild10
Swelling: Moderate00
Swelling: Severe00
Tenderness: Any4247
Tenderness: Mild3237
Tenderness: Moderate1314
Tenderness: Severe00
PrimaryNumber of Participants Reporting Local Reaction Within 5 Days After Dose 2 in MDV and SDS Group

Local reactions were reported within 5 days (day 2 to day 6) using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurt if gently touched; Moderate (hurt if gently touched with crying); Severe (caused limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.1 to 7.0 cm); Severe (greater than \[\>\] 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 5 days after Dose 2 (Day 2 to Day 6) of the infant series
Reported as:
Number · participants
Number of Participants Reporting Local Reaction Within 5 Days After Dose 2 in MDV and SDS Group
participants13vPnC Multi-dose Vial (MDV)13vPnC Single-Dose Syringe (SDS)
Redness: Any (n=247, 247)20
Redness: Mild (n=247, 247)20
Redness: Moderate (n=247, 247)00
Redness: Severe (n=247, 247)00
Swelling: Any (n=247, 247)20
Swelling: Mild (n=247, 247)20
Swelling: Moderate (n=247, 247)10
Swelling: Severe (n=247, 247)00
Tenderness: Any (n=248, 247)3432
Tenderness: Mild (n=248, 247)2728
Tenderness: Moderate (n=247, 247)75
Tenderness: Severe (n=247, 247)00
PrimaryNumber of Participants Reporting Local Reaction Within 5 Days After Dose 3 in MDV and SDS Group

Local reactions were reported within 5 days (day 2 to day 6) using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurt if gently touched; Moderate (hurt if gently touched with crying); Severe (caused limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.1 to 7.0 cm); Severe (greater than \[\>\] 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 5 days after Dose 3 (Day 2 to Day 6) of the infant series
Reported as:
Number · participants
Number of Participants Reporting Local Reaction Within 5 Days After Dose 3 in MDV and SDS Group
participants13vPnC Multi-dose Vial (MDV)13vPnC Single-Dose Syringe (SDS)
Redness: Any00
Redness: Mild00
Redness: Moderate00
Redness: Severe00
Swelling: Any00
Swelling: Mild00
Swelling: Moderate00
Swelling: Severe00
Tenderness: Any3735
Tenderness: Mild3032
Tenderness: Moderate94
Tenderness: Severe00
PrimaryNumber of Participants Reporting Systemic Events Within 5 Days After Dose 1 in MDV and SDS Group

Systemic events (any fever greater than or equal to \[\>=\] 38.0 degrees Celsius \[C\], decreased appetite was scaled as; Moderate (decreased oral intake); Severe (refusal to feed). Irritability scaled as; Mild (easily consolable); Moderate (requiring increased attention); Severe (Inconsolable, crying that cannot be comforted). Increased sleep was scale as; mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (Disabling not interested in usual daily activity) and use of antipyretic medication were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 5 days after Dose 1 (Day 2 to Day 6) of infant series
Reported as:
Number · participants
Number of Participants Reporting Systemic Events Within 5 Days After Dose 1 in MDV and SDS Group
participants13vPnC Multi-dose Vial (MDV)13vPnC Single-Dose Syringe (SDS)
Fever: >=38.0 degree C (n=248, 250)97
Fever: >=38.0 but <=39.0 degrees C (n=248, 250)97
Fever: >39.0 but <=40.0 degrees C (n=248, 250)00
Fever: >40.0 degrees C (n=248, 250)00
Decreased appetite: Any (n=248, 250)1726
Decreased appetite: Moderate (n=248, 250)1726
Decreased appetite: Severe (n=248, 250)00
Irritability: Any (n=249, 250)10393
Irritability: Mild (n=249, 250)8677
Irritability: Moderate (n=248, 250)1917
Irritability: Severe (n=248, 250)00
Increased sleep: Any (n=248, 250)1614
Increased sleep: Mild (n=248, 250)1110
Increased sleep: Moderate (n=248, 250)64
Increased sleep: Severe (n=248, 250)00
Use of antipyretic medication (n=248, 250)5558
PrimaryNumber of Participants Reporting Systemic Events Within 5 Days After Dose 2 in MDV and SDS Group

Systemic events (any fever greater than or equal to \[\>=\] 38.0 degrees Celsius \[C\], decreased appetite was scaled as; Moderate (decreased oral intake); Severe (refusal to feed). Irritability scaled as; Mild (easily consolable); Moderate (requiring increased attention); Severe (Inconsolable, crying that cannot be comforted). Increased sleep was scale as; mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (Disabling not interested in usual daily activity) and use of antipyretic medication were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 5 days after Dose 2 (Day 2 to Day 6) of infant series
Reported as:
Number · participants
Number of Participants Reporting Systemic Events Within 5 Days After Dose 2 in MDV and SDS Group
participants13vPnC Multi-dose Vial (MDV)13vPnC Single-Dose Syringe (SDS)
Fever: >=38.0 degree C (n=247, 247)77
Fever: >=38.0 but <=39.0 degrees C (n=247, 247)77
Fever: >39.0 but <=40.0 degrees C (n=247, 247)10
Fever: >40.0 degrees C (n=247, 247)00
Decreased appetite: Any(n=247, 247)2818
Decreased appetite: Moderate (n=247, 247)2818
Decreased appetite: Severe (n=247, 247)00
Irritability: Any (n=248, 247)9383
Irritability: Mild (n=248, 247)7567
Irritability: Moderate (n=247, 247)2317
Irritability: Severe (n=247, 247)03
Increased sleep: Any (n=247, 247)2414
Increased sleep: Mild (n=247, 247)2012
Increased sleep: Moderate (n=247, 247)41
Increased sleep: Severe (n=247, 247)01
Use of antipyretic medication (n=248, 247)4643
PrimaryNumber of Participants Reporting Systemic Events Within 5 Days After Dose 3 in MDV and SDS Group

Systemic events (any fever greater than or equal to \[\>=\] 38.0 degrees Celsius \[C\], decreased appetite was scaled as; Moderate (decreased oral intake); Severe (refusal to feed). Irritability scaled as; Mild (easily consolable); Moderate (requiring increased attention); Severe (Inconsolable, crying that cannot be comforted). Increased sleep was scale as; mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (Disabling not interested in usual daily activity) and use of antipyretic medication were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 5 days after Dose 3 (Day 2 to Day 6) of infant series
Reported as:
Number · participants
Number of Participants Reporting Systemic Events Within 5 Days After Dose 3 in MDV and SDS Group
participants13vPnC Multi-dose Vial (MDV)13vPnC Single-Dose Syringe (SDS)
Fever: >=38.0 degree C (n=246, 241)38
Fever: >=38.0 but <=39.0 degrees C (n=246, 241)37
Fever: >39.0 but <=40.0 degrees C (n=246, 241)01
Fever: >40.0 degrees C (n=246, 241)00
Decreased appetite: Any (n=246, 242)2420
Decreased appetite: Moderate (n=246, 242)2419
Decreased appetite: Severe (n=246, 241)01
Irritability: Any (n=246, 243)8392
Irritability: Mild (n=246, 242)7174
Irritability: Moderate (n=246, 242)1518
Irritability: Severe (n=246, 241)15
Increased sleep: Any (n=246, 241)1212
Increased sleep: Mild (n=246, 241)1011
Increased sleep: Moderate (n=246, 241)21
Increased sleep: Severe (n=246, 241)10
Use of antipyretic medication (n=246, 241)3436
PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Infant Series

An AE was any untoward medical occurrence in a participants who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 to 42 days after last dose that were absent before treatment or that worsened relative to pretreatment state

Time frame:
Dose 1 up to 28 to 42 days after dose 3
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Infant Series
participants13vPnC Multi-dose Vial (MDV)13vPnC Single-Dose Syringe (SDS)
AEs123127
SAEs10
PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Prior to Dose 1

An AE was any untoward medical occurrence in a participants who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Adverse events were also reported in participants who provided consent but were not randomized in this study. The data of these participants has been reported under 'Screened Only' arm.

Time frame:
Informed consent up to Dose 1
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Prior to Dose 1
participants13vPnC Multi-dose Vial (MDV)13vPnC Single-Dose Syringe (SDS)Screened Only
AEs209
SAEs000
SecondaryPercentage of Participants Achieving a Serotype-Specific Opsonophagocytic Activity (OPA) Titer >= Lower Limit of Quantitation (LLOQ) 1 Month After Infant Series

Percentage of participants achieving OPA Titer \>= lower limit of quantitation (LLOQ) along with 95% CI for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Exact 2-sided confidence interval (Clopper and Pearson) based on the observed proportion of participants. Here "n"= Number of participants with an antibody titer ≥ LLOQ for the given serotype.

Time frame:
1 month after the infant series
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Serotype-Specific Opsonophagocytic Activity (OPA) Titer >= Lower Limit of Quantitation (LLOQ) 1 Month After Infant Series
percentage of participants13vPnC Multi-dose Vial (MDV)13vPnC Single-Dose Syringe (SDS)
Serotype 1 (n=159,160)71.7 (64.0 to 78.5)79.4 (72.3 to 85.4)
Serotype 3 (n=160,160)98.8 (95.6 to 99.8)100.0 (97.7 to 100.0)
Serotype 4 (n=159,159)100.0 (97.7 to 100.0)100.0 (97.7 to 100.0)
Serotype 5 (n=160,159)83.1 (76.4 to 88.6)85.5 (79.1 to 90.6)
Serotype 6A (n=160,160)99.4 (96.6 to 100.0)99.4 (96.6 to 100.0)
Serotype 6B (n=156,155)96.8 (92.7 to 99.0)96.8 (92.6 to 98.9)
Serotype 7F (n=159,160)100.0 (97.7 to 100.0)100.0 (97.7 to 100.0)
Serotype 9V (n=158,160)79.7 (72.6 to 85.7)75.0 (67.6 to 81.5)
Serotype 14 (n=157,160)81.5 (74.6 to 87.3)89.4 (83.5 to 93.7)
Serotype 18C (n=159,160)99.4 (96.5 to 100.0)99.4 (96.6 to 100.0)
Serotype 19A (n=160,160)95.6 (91.2 to 98.2)97.5 (93.7 to 99.3)
Serotype 19F (n=158,159)93.7 (88.7 to 96.9)94.3 (89.5 to 97.4)
Serotype 23F (n=159,160)96.2 (92.0 to 98.6)97.5 (93.7 to 99.3)
Statistical analysis
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: -7.7 · 95% CI -17.2 to 1.9
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: -1.2 · 95% CI -4.4 to 1.1
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: 0.0 · 95% CI -2.3 to 2.3
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: -2.4 · 95% CI -10.6 to 5.7
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: 0.0 · 95% CI -2.9 to 2.8
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: 0.0 · 95% CI -4.5 to 4.6
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: 0.0 · 95% CI -2.3 to 2.3
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: 4.7 · 95% CI -4.5 to 14.1
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: -7.8 · 95% CI -15.8 to -0.0
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: -0.0 · 95% CI -2.9 to 2.9
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: -1.9 · 95% CI -6.6 to 2.4
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: -0.7 · 95% CI -6.3 to 4.9
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Percent difference: -1.3 · 95% CI -5.8 to 3.0
SecondarySerotype-Specific Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After the Infant Series

Antibody geometric mean titers as measured by OPA assay for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. GMTs were calculated using all participants with available data for the specified blood draw. CIs were back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers. Here "n"= participants evaluable =specified category.

Time frame:
1 month after the infant series
Reported as:
Geometric mean · titer
Serotype-Specific Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After the Infant Series
titer13vPnC Multi-dose Vial (MDV)13vPnC Single-Dose Syringe (SDS)
Serotype 1 (n=159,160)48 (39.0 to 58.0)52 (43.2 to 62.6)
Serotype 3 (n=160,160)97 (87.3 to 108.8)122 (110.1 to 135.7)
Serotype 4 (n=159,159)1666 (1412.3 to 1966.3)1492 (1285.2 to 1732.3)
Serotype 5 (n=160,159)79 (67.7 to 92.4)80 (69.1 to 92.6)
Serotype 6A (n=160,160)1690 (1460.5 to 1955.9)1968 (1698.5 to 2279.3)
Serotype 6B (n=156,155)1990 (1611.7 to 2456.9)2014 (1639.1 to 2475.4)
Serotype 7F (n=159,160)2891 (2565.4 to 3258.5)3450 (3014.7 to 3947.9)
Serotype 9V (n=158,160)709 (600.5 to 836.2)706 (597.0 to 835.3)
Serotype 14 (n=157,160)567 (415.4 to 773.5)786 (607.8 to 1015.3)
Serotype 18C (n=159,160)2792 (2387.5 to 3264.8)1605 (1352.0 to 1904.4)
Serotype 19A (n=160,160)305 (256.2 to 362.9)329 (284.8 to 379.8)
Serotype 19F (n=158,159)430 (357.6 to 517.1)470 (391.4 to 565.3)
Serotype 23F (n=159,160)918 (729.0 to 1156.4)998 (810.6 to 1229.6)
Statistical analysis
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmt ratio: 0.9 · 95% CI 0.70 to 1.20
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmt ratio: 0.8 · 95% CI 0.69 to 0.93
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmt ratio: 1.1 · 95% CI 0.89 to 1.39
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmt ratio: 1.0 · 95% CI 0.80 to 1.22
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmt ratio: 0.9 · 95% CI 0.70 to 1.06
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmt ratio: 1.0 · 95% CI 0.74 to 1.33
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmt ratio: 0.8 · 95% CI 0.70 to 1.00
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmt ratio: 1.0 · 95% CI 0.79 to 1.27
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmt ratio: 0.7 · 95% CI 0.48 to 1.08
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmt ratio: 1.7 · 95% CI 1.38 to 2.19
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmt ratio: 0.9 · 95% CI 0.74 to 1.16
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmt ratio: 0.9 · 95% CI 0.71 to 1.18
  • 13vPnC Multi-dose Vial (MDV) vs 13vPnC Single-Dose Syringe (SDS) · Gmt ratio: 0.9 · 95% CI 0.67 to 1.25

Adverse events

Collected over Adverse events (AEs)/serious AEs (SAEs): recorded from signing of informed consent form to 28 to 42 days after dose 3. Pre-specified AEs were recorded in an electronic diary: local reactions, systemic events (Day 2 to Day 6 after each vaccination). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC MDV: Informed Consent to Dose 1—0/250 (0%)2/250 (0.8%)
13vPnC SDS: Informed Consent to Dose 1—0/250 (0%)0/250 (0%)
13vPnC MDV: After Dose 1—0/250 (0%)113/250 (45.2%)
13vPnC SDS: After Dose 1—0/250 (0%)107/250 (42.8%)
13vPnC MDV: After Dose 2—0/249 (0%)114/249 (45.8%)
13vPnC SDS: After Dose 2—0/248 (0%)99/248 (39.9%)
13vPnC MDV: After Dose 3—1/247 (0.4%)97/247 (39.3%)
13vPnC SDS: After Dose 3—0/244 (0%)102/244 (41.8%)
Screened Only—0/26 (0%)9/26 (34.6%)
Most frequent serious events
Most frequent serious events
Event13vPnC MDV: Informed Consent to Dose 113vPnC SDS: Informed Consent to Dose 113vPnC MDV: After Dose 113vPnC SDS: After Dose 113vPnC MDV: After Dose 213vPnC SDS: After Dose 213vPnC MDV: After Dose 313vPnC SDS: After Dose 3Screened Only
Sudden infant death syndromeGeneral disorders0/2500/2500/2500/2500/2490/2481/2470/2440/26
Most frequent other events
Showing 10 of 74
Most frequent other events
Event13vPnC MDV: Informed Consent to Dose 113vPnC SDS: Informed Consent to Dose 113vPnC MDV: After Dose 113vPnC SDS: After Dose 113vPnC MDV: After Dose 213vPnC SDS: After Dose 213vPnC MDV: After Dose 313vPnC SDS: After Dose 3Screened Only
Irritability: AnyGeneral disorders——103/24993/25093/24883/24783/24692/2430/26
Irritability: MildGeneral disorders——86/24977/25075/24867/24771/24674/2420/26
Tenderness: AnySkin and subcutaneous tissue disorders——42/24847/25034/24832/24737/24635/2410/26
Tenderness: MildSkin and subcutaneous tissue disorders——32/24837/25027/24828/24730/24632/2410/26
Failure to thriveMetabolism and nutrition disorders0/2500/2500/2500/2500/2490/2480/2471/2443/26
Decreased appetite: AnyGeneral disorders——17/24826/25028/24718/24724/24620/2420/26
Decreased appetite: ModerateGeneral disorders——17/24826/25028/24718/24724/24619/2420/26
Upper respiratory tract infectionInfections and infestations1/2500/25027/25017/25017/24910/24819/24725/2440/26
Increased sleep: AnyGeneral disorders——16/24814/25024/24714/24712/24612/2410/26
Irritability: ModerateGeneral disorders——19/24817/25023/24717/24715/24618/2420/26

Baseline characteristics

Safety population included all participants who received at least 1 dose of investigational product.

Age, Continuous
Age, Continuous(days)13vPnC Multi-dose Vial (MDV)13vPnC Single-Dose Syringe (SDS)Total
Mean57.3 ± 8.656.9 ± 8.857.1 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC Multi-dose Vial (MDV)13vPnC Single-Dose Syringe (SDS)Total
Female129130259
Male121120241
08

Study locations

2 sites
  • Medical Research Council Unit, The Gambia
    Fajara, The Gambia, West Africa 000273, Gambia
  • Fajikunda Major Health Centre
    Ksmd, The Gambia, Gambia
09

References and documents

Publications

  • Idoko OT, Mboizi RB, Okoye M, Laudat F, Ceesay B, Liang JZ, Le Dren-Narayanin N, Jansen KU, Gurtman A, Center KJ, Scott DA, Kampmann B, Roca A. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: An open-label randomized controlled trial. Vaccine. 2017 May 31;35(24):3256-3263. doi: 10.1016/j.vaccine.2017.04.049. Epub 2017 May 4. PubMed 28479175 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2013
First posted
Oct 17, 2013
Start
Jan 2014
Primary completionActual
Sep 2014
CompletionActual
Sep 2014
Results first posted
Mar 13, 2015
Last update
Mar 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01964716
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 17, 2013
Start date
Jan 2014
Primary completion
Sep 2014
Completion
Sep 2014
Results posted
Mar 13, 2015
Last update
Mar 13, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion